Genzyme Corporation

Introduction

This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

* Gain insight into Genzyme's strategic outlook across the next 6 years
* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Strategic insight into the prospects for Genzyme over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

* Benchmark Genzyme's performance against key rivals in the prescription pharmaceutical sector
* Assess the impact of the Allston Landing contamination issues to the company's top line sales performance
* Understand the level of sales growth and portfolio diversification Genzyme will offer Sanofi-Aventis, post acquisition

[Studien Infos ausblenden]

Executive Summary
Key findings
Genzyme prescription pharma sales outlook
Genzyme financial outlook
Key developments
Sanofi-Aventis to acquire Genzyme
Daiichi Sankyo and Genzyme file lawsuit against Watson
Additional manufacturing plant in Geel
Genetic testing business sold to Laboratory Corporation of America
First milestones of FDA consent decree met
Roche obtains sublicense for EGFR lung cancer assays from Genzyme
Genzyme enters into asset purchase agreement with Sekisui Chemical
Phase III leukemia trial fails primary endpoint
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Strategic insight
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
STRATEGIC INSIGHT
Genzyme success in ultra-niche markets
With the blockbuster model under threat, Genzyme’s niche market strategy looks set to hold firm
Greater economies of scale as rare genetic disorders franchise expands
Prudent risk-spreading strategy
Combination of recent problems and strong growth potential made Genzyme an attractive acquisition target
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Bone Care International
AnorMED acquisition
Bioenvision
Current corporate structure
Biotherapeutics
LSDs
Genetics/diagnostics
Divestment announced
Sekisui Chemical acquires Genzyme’s diagnostic products division
LabCorp acquires Genzyme Genetics
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2004–16
Product analysis
Product analysis, 2004–10
Product analysis, 2010–16
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2010–16
Core analysis, 2010–16
Expiry analysis, 2010–16
Launch/core/expiry configuration, 2010–16
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Operating costs and profit analysis
Operating costs and profit analysis, 2004–10
Operating cost ratio and profit margin analysis, 2004–10
Operating cost ratio and profit margin analysis, 2010–16
Operating costs and profit analysis, 2010–16
PRODUCT AND PIPELINE ANALYSIS
Overview
Myozyme/Lumizyme
Cerezyme
Mozobil
Fabrazyme
Lemtrada
Renagel/Renvela
Genzyme pipeline overview

[Inhaltsverzeichnis ausblenden]